Patients must have a forced expiratory volume in one second (FEV-) and diffusing capacity of the lung for carbon monoxide (DLCO) > % predicted
Pulmonary function tests within  months of study enrollment must have forced expiratory volume in  second (FEV) >= . L and diffusing capacity of the lung for carbon monoxide (DLCO) >= % of predicted; patients with FEV of < . L but a predicted value of >= % may be eligible after review of the case by the study radiation primary investigator (PI) or his designee
Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? % (adjusted for hemoglobin) and forced expiratory volume in one second (FEV) ? %
Participant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ? % predicted and/or forced expiratory volume in  second (FEV) ? % predicted.
Forced expiratory volume in one second (FEV) or diffusing capacity of the lung for carbon monoxide (DLCO) < % or need for use of supplemental oxygen
Forced expiratory volume in one second (FEV) of < % predicted or carbon monoxide diffusing capacity (DLCO) (corrected) < % (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing)
Carbon monoxide diffusing capacity (DLCO) and forced expiratory volume in  second (FEV) > % predicted
Pulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in  second (FEV ) and DLCO should be greater than % of predicted normal value
Participant must be considered ineligible for induction therapy defined by the following: a. >=  years of age; or b. >=  to  years of age with at least one of the following comorbidities: i. Eastern Cooperative Oncology Group (ECOG) Performance Status of  or ; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction <= % or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) <= % or Forced Expiratory Volume in  second (FEV) <= %; iv. Creatinine clearance >=  mL/min to <  ml/min; v. Moderate hepatic impairment with total bilirubin > . to <= .  Upper Limit of Normal (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Medical Director during screening and before study enrollment.
Major organ dysfunction defined as:\r\n* Creatinine clearance <  ml/min\r\n* Significant hepatic dysfunction (serum glutamic-oxaloacetic transaminase [SGOT] >  x upper limit of normal; bilirubin > . mg/dL)\r\n* Forced expiratory volume in  second (FEV) of < % predicted or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < % (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing)
Adequate pulmonary function, defined as ? grade  dyspnea and saturated oxygen (SaO) >= % on room air; if pulmonary function test (PFT)s are performed based on the clinical judgment of the treating physician, patients with forced expiratory volume in  second (FEV) >= % of predicted and carbon monoxide diffusing capability (DLCO) (corrected) of >= % of predicted will be eligible
Known forced expiratory volume in  second (FEV) or corrected carbon monoxide diffusing capability (cDLCO) < % of predicted
Oxygen saturation >= % on room air; pulmonary function test (PFT)s required only if symptomatic or prior known impairment - must have pulmonary function > % corrected carbon monoxide diffusing capability (DLCO) and forced expiratory volume in  second (FEV) (within  days of study registration)
No significant obstructive airways disease (forced expiratory volume in  second [FEV] must be >= %) and must have acceptable diffusion capacity (corrected carbon monoxide diffusing capability [DLCO] > % of predicted)
Clinically significant pulmonary dysfunction, as determined by medical history and physical examination; patients with a history of pulmonary dysfunction must have pulmonary function tests with a forced expiratory volume in  second (FEV) >= % of predicted and a diffusing capacity of the lung for carbon monoxide (DLCO) >= % (corrected for hemoglobin)
?  to  years of age and fulfill at least one criteria associated with lack of fitness for intensive induction chemotherapy: i. Eastern Cooperative Oncology Group (ECOG) Performance status of  - ; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction ? % or chronic stable angina; iii. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) ? % or Forced Expiratory Volume in  second(FEV) ? %; iv. Creatinine clearance ?  mL/min to <  ml/min; v. Moderate hepatic impairment with total bilirubin > . to ? .  Upper Limit of Normal (ULN); vi. Other comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy which must be reviewed and approved by the study medical monitor before study enrollment.
Carbon monoxide diffusing capability test (DLCO) (adjusted for hemoglobin) >= % of predicted and forced expiratory volume in  second (FEV-) >= %
Oxygen saturation >= % on room air; if symptomatic or prior known impairment, pulmonary function >= % corrected diffusing capacity of the lungs for carbon monoxide (DLCO) and forced expiratory volume (FEV) is required, within  days of study registration (within  days for pulmonary and cardiac assessments)
Forced expiratory volume in  second (FEV) and carbon monoxide diffusing capability test (DLCO) >= % predicted (or per institutional standard)
Low likelihood of being eligible for reduced intensity conditioning HCT based on known information\r\n* Cardiac ejection fraction < % or symptomatic coronary artery disease or uncontrolled arrhythmia\r\n* Diffusing capacity of the lungs for carbon monoxide (DLCOc) < % or forced expiratory volume in  second (FEV) < %\r\n* Estimated glomerular filtration rate (GFR) <  ml/min\r\n* Need for supplemental oxygen\r\n* Direct bilirubin or alanine aminotransferase (ALT) >  x upper limit of normal, unless these abnormalities are thought to be related to Gilberts disease or leukemic infiltration of hepatic parenchyma
Have adequate pulmonary function to tolerate surgery; patients must have a diffusing lung capacity for carbon monoxide (DLCO) > % of predicted post operative forced expiratory volume in  second (FEV) (ppoFEV) > % of predicted
Adequate pulmonary function, defined as Common Terminology Criteria for Adverse Events (CTCAE) grade =<  dyspnea and oxygen saturation (SaO) >= % on room air; patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing and must have a forced expiratory volume in  second (FEV) >= % of predicted value or diffusing capacity of the lung for carbon monoxide (DLCO; corrected) >= % of predicted value
Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with a forced expiratory volume in  second (FEV) of =< % or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < % will be excluded
Diffusing capacity divided by the alveolar volume (DDLCO/VA) and forced expiratory volume (FEV)  . > % of predicted on pulmonary function tests
Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in  second (FEV) < . L or diffusion capacity of the lung for carbon monoxide (DLco) (corrected [corr] for hemoglobin [Hgb]) < % will be excluded
DLCO (diffusing capacity of the lung for carbon monoxide) >= % of predicted corrected for hemoglobin, FEV- (forced expiratory volume at  second) >= % of predicted
Diffusing capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in one second (FEV) > % predicted
Forced expiratory volume in one second (FEV) > % of predicted measured, or diffusing capacity of the lung for carbon monoxide (DLCO) > % of predicted measured
Within  days of registration: pulmonary function tests (PFTs) including forced expiratory volume in one second (FEV-) and diffusing capacity of the lung for carbon monoxide (DLCO)
Carbon monoxide diffusing capability test (DLCO) or forced expiratory volume in  second (FEV) < % predicted
Diffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in  second (FEV) > % predicted
Pulmonary-forced expiratory volume in  second (FEV) or carbon monoxide diffusing capability (DLco) < % or need for use of supplemental oxygen
Clinically significant pulmonary dysfunction, as determined by medical history and physical exam. Patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in  second (FEV) < . L or carbon monoxide diffusing capability (DLco) (correlation for hemoglobin [corr for Hgb]) < % will be excluded.
Clinically significant pulmonary dysfunction, as determined by medical history and physical exam. Patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV) < % of normal or carbon monoxide diffusing capacity (DLco) (corrected [corr] for hemoglobin [Hgb]) < % will be excluded.
Within  days of registration: Corrected carbon monoxide diffusing capability (DLCO) and forced expiratory volume in  second (FEV), >= % predicted
Clinically significant pulmonary dysfunction, as determined by medical history and physical examination; patients with a history of pulmonary dysfunction must have pulmonary function tests with a forced expiratory volume in  second (FEV) >= % of predicted and a diffusing capacity of the lung for carbon monoxide (DLCO) >= % (corrected for hemoglobin)
Diffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in  second (FEV) > % predicted
Patients with a diffusing capacity of the lung for carbon monoxide (DLCO) < % of normal or a forced expiratory volume in one second (FEV) < % of normal, based on either NIH or United States (USA) normal ranges
Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function tests (PFTs) (e.g. forced expiratory volume in  second [FEV] or carbon monoxide diffusing capability [DLCO] % or less of predicted or oxygen [O] saturation % or less at rest on room air)
Clinically significant pulmonary dysfunction, as determined by medical history and physical exam. Patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV) < . L or diffusion lung capacity [DLCO] corrected [corr] for hemoglobin [Hgb]) < % will be excluded.
Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in  second (FEV) < . L or diffusion capacity of the lungs for carbon monoxide (DLCO) (corrected for Hb) < % will be excluded
Forced expiratory volume in one second (FEV) >= % or diffusing capacity of the lungs for carbon monoxide (DLCO) (hemoglobin [Hb]) >= % of predicted, unless pulmonary dysfunction is deemed to be due to chronic GVHD
Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin > %; and forced expiratory volume in one second (FEV) > %
Diffusing capacity of the lung for carbon monoxide (DLCO)/alveolar volume (VA) and forced expiratory volume in  second (FEV-.) >= % of predicted on pulmonary function tests
Pulmonary function of diffusing capacity of the lung for carbon monoxide (DLCO) adjusted for alveolar volume (adj/VA) and forced expiratory volume in one second (FEV) >= % of normal indices for age and height unless the patient has a likely acute reversible etiology of decline and then DLCO adj/VA >= % of normal; pediatric patients unable to complete pulmonary function tests (PFTs) may be enrolled as per enrolling institution standard operating procedure (SOP) for recipient guidelines
Diffusing capacity of the lung for carbon monoxide (DLCO) < %, total lung capacity (TLC) < %, forced expiratory volume in one second (FEV) < % and/or receiving supplementary continuous oxygen
Must have adequate lung function defined within  days prior to registration as: () forced expiratory volume in  second (FEV) > % of predicted or >  ml, () diffusing capacity of the lung for carbon monoxide (DLCO) >  % predicted
Diffusing capacity of the lung for carbon monoxide (DLCO) < %, total lung capacity (TLC) < %, forced expiratory volume in  second (FEV) < % and/or requiring continuous supplementary oxygen, or severe deficits in pulmonary function testing as defined by pulmonary consultant service; and the FHCRC principal investigator (PI) of the study must approve of enrollment of all patients with pulmonary nodules
Pulmonary dysfunction as measured by a corrected diffusing capacity of the lung for carbon monoxide (DLCO) < % of predicted total lung capacity (TLC) < %, forced expiratory volume in  second (FEV) < % and/or receiving supplementary continuous oxygen; the FHCRC principal investigator (PI) of the study must approve enrollment of all patients with pulmonary nodules
Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV) < . L or diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin [Hgb]) < % will be excluded
Pulmonary function: > % corrected diffusing capacity of carbon monoxide (DLCO) and forced expiratory volume in one second (FEV) (oxygen saturation [> %] can be used in child where pulmonary function tests [PFT's] cannot be obtained)
Greater than or equal to (>=)  years of age or >=  up to  years of age and have at least one of the following: congestive heart failure or ejection fraction less than or equal to (<=)  percent; creatinine greater than (>)  milligram per deciliter (mg/dL); dialysis or prior renal transplant; documented pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) <=  percent of expected, or forced expiratory volume in  second (FEV) <=  percent of expected or dyspnea at rest requiring oxygen; eastern cooperative oncology group (ECOG) performance status of ; prior or current malignancy that does not require concurrent treatment; unresolved infection; comorbidity that, in the Investigator's opinion, makes the participant unsuitable for intensive chemotherapy and must be documented and approved by the Sponsor before randomization
Forced expiratory volume in  second (FEV) > % of predicted and diffusing capacity of the lung for carbon monoxide (DLCO) >= % of predicted
Chest x-ray (CXR) or computed tomography CT within  weeks prior to Day  with no evidence of pulmonary congestion, pleural effusions, pulmonary fibrosis, or significant emphysema. If results are questionable, patients should have additional lung function testing to exclude clinically relevant restriction or obstruction. Patients must have a forced expiratory volume (FEV-) and Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) of at least % and % of expected, respectively.
Pulmonary function test including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in  second (FEV) and DLCO should be greater than % of predicted normal value
Carbon monoxide diffusing capability test (DLCO) >= % (adjusted for hemoglobin) and forced expiratory volume in  second (FEV) >= %
Pulmonary function: carbon monoxide diffusing capability test (DLCO) >= % (adjusted for hemoglobin) and forced expiratory volume in  second (FEV) >= %
Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? % (adjusted for hemoglobin) and forced expiratory volume in one second (FEV) ? %
